Because skin malignancies often herald internal or systemic malignancies, knowing the link between primary and metastatic sites can impact staging, prognosis and management – and in some cases, save lives.
Immunosuppressed patient with recurrent squamous cell carcinoma succumbs to death. Was the dermatologist who did his skin evaluations negligent?
Researchers at Mayo Clinic’s Jacksonville, Fla., campus reported a discovery that could be the code for reprogramming cancer cells back to normal.
Due to the complexities and follow-up requirements of nonsurgical treatments for skin cancer, patient selection is critical. Expert offers tips for using various noninvasive treatment options for BCC, SCC, and melanoma.
Ongoing research is trying to identify strategies for overcoming resistance of advanced basal cell carcinoma to targeted therapy with a Hedgehog inhibitor. High level evidence to support adjuvant radiotherapy for high-risk non-melanoma skin cancers is lacking, but certain patients warrant evaluation by a multidisciplinary tumor board and treatment with adjuvant radiotherapy based on their risk for recurrence.
Advances in research have led to the emergence of medical therapies for BCCs; more research is needed to develop systemic therapies to treat SCCs.
Many patients and physicians have the misconception that the Hispanic population is not prone to skin cancer. As a result, these patients are not being diagnosed early.
Dr. Goldberg discusses five patient gifting situations. Are any of these acceptable?
New and advancing forms of technology could improve the detection and treatment of melanoma.
Some patients respond more rapidly to immune therapies like ipilimumab, and clinicians have observed delayed toxicities with prolonged use of checkpoint inhibitors; effective treatments for subtypes of melanoma, such as uveal melanoma, have not yet emerged.